Expression of the ERM family members (ezrin, radixin and moesin) in breast cancer

Fernando,Herman; Martin,Tracey A.; Douglas-Jones,Anthony; Kynaston,Howard G.; Mancel,Robert E.; Jiang,Wen G.

doi:10.3892/etm_00000025

Expression of the ERM family members (ezrin, radixin and moesin) in breast cancer

Authors:
- Herman Fernando
- Tracey A. Martin
- Anthony Douglas-Jones
- Howard G. Kynaston
- Robert E. Mancel
- Wen G. Jiang
View Affiliations

Affiliations: Metastasis and Angiogenesis Research Group, Wales College of Medicine, Cardiff University, Cardiff, UK
Published online on: January 1, 2010 https://doi.org/10.3892/etm_00000025
Pages: 153-160

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The ERM family is composed of the proteins ezrin, moesin and radixin, which are cell structure-related proteins. Despite the detection of viable roles of ERM family proteins, the impact of these molecules in cancer pathogenesis has yet to be investigated. Evidence emerging from clinical and translational studies showed that the ERM family is linked to disease progression in clinical cancers. We aimed to establish the pattern of expression of the ERM proteins and deduce a possible relationship between these molecules and clinical outcome in a cohort of human breast cancers. The expression of the three ERM molecules at the mRNA and protein levels in a cohort of 122 human breast cancers and 32 normal breast tissues were analysed and correlated with pathological and clinical information as well as patient outcome. The three molecules were positively stained in mammary tissues while the staining pattern was lost in the malignant cells. Low levels of moesin and radixin transcripts were seen in tumours from patients with metastasis, local recurrence and in patients who succumbed to the disease (moesin: p=0.039, p=0.037 and p=0.066, respectively, and radixin: p=0.039, p=0.039 and p=0.04, respectively). Ezrin levels were significantly lower in tumour recurrence and in patients who succumbed to the disease (p=0.0001 and p=0.59, respectively). Using the Kaplan-Meier survival analysis, a general trend of higher levels of ERM was observed, with marginal long overall and disease-free survival. In conclusion, an inverse relationship between ERM expression and tumour behaviour of breast cancer patients was noted. However, further work needs to be conducted in other types of cancer in clinical situations to obtain consistent results.

View Figures

View References

1.	Sato N, Funayama N, Nagafuchi A, Yonemura S and Tsukita S: A gene family consisting of ezrin, radixin and moesin. Its specific localization at actin filament/plasma membrane association sites. J Cell Sci. 103:131–143. 1992.
2.	Pataky F, Pironkova R and Hudspeth AJ: Radixin is a constituent of stereocilia in hair cells. Proc Natl Acad Sci USA. 101:2601–2606. 2004.
3.	Faure S, Salazar-Fontana LI, Semichon M, Tybulewicz VL, Bismuth G, Trautmann A, Germain RN and Delon J: ERM proteins regulate cytoskeleton relaxation promoting T cell-APC conjugation. Nat Immunol. 5:272–279. 2004.
4.	Vaheri A, Carpén O, Heiska L, Helander TS, Jääskeläinen J, Majander-Nordenswan P, Sainio M, Timonen T and Turunen O: The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Curr Opin Cell Biol. 9:659–666. 1997.
5.	Hiscox S and Jiang WG: Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/β-catenin. J Cell Sci. 112:3081–3090. 1999.
6.	Mhawech-Fauceglia P, Dulguerov P, Beck A, Bonet M and Allal AS: Value of ezrin, maspin and nm23-H1 protein expressions in predicting outcome of patients with head and neck squamous-cell carcinoma treated with radical radiotherapy. J Clin Pathol. 60:185–189. 2007.
7.	Valdman A, Fang X, Pang ST, Nilsson B, Ekman P and Egevad L: Ezrin expression in prostate cancer and benign prostatic tissue. Eur Urol. 48:852–857. 2005.
8.	Weng WH, Ahlen J, Astrom K, Lui WO and Larsson C: Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res. 11:6198–6204. 2005.
9.	Bruce B, Khanna G, Ren L, Landberg G, Jirstrom K, Powell C, Borczuk A, Keller ET, Wojno KJ, Meltzer P, Baird K, McClatchey A, Bretscher A, Hewitt SM and Khanna C: Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis. 24:69–78. 2007.
10.	Hanavadi S, Martin T, Mansel R and Jiang WG: Interleukin-11 and its receptor expression in human breast cancer. Ann Surg Oncol. 13:802–808. 2006.
11.	Martin T, Goyal A, Mansel R, Watkins G and Jiang W: The transcription factor for the E-cadherin complex, Twist, Slug and Snail, in human breast cancer. Ann Surg Oncol. 12:1–9. 2005.
12.	Jiang WG, Watkins G, Lane J, Cunnick G, Douglas-Jones A, Mokbel K and Mansel R: Prognostic value of Rho family and rho-GDIs in breast cancer. Clin Cancer Res. 9:6432–6440. 2003.
13.	Jiang WG, Douglas-Jones A and Mansel R: Level of expression of PPAR-gamma and its co-activator (PPAR-GCA) in human breast cancer. Int J Cancer. 106:752–757. 2003.
14.	Nazarenko A, Bhatnagar S and Hohman R: A closed tube format for amplification and detection of DNA based on energy transfer. Nucleic Acids Res. 25:2516–2521. 1997.
15.	Parr C, Watkins G and Jiang WG: The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumor clinicopathological parameters in human breast cancer. Int J Mol Med. 14:779–786. 2004.
16.	Jiang WG, Grimshaw D, Lane J, Martin T, Abounader R, Laterra J and Mansel RE: A hammerhead ribozyme suppresses expresion of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clin Cancer Res. 7:2555–2562. 2001.
17.	Ye L, Martin T, Parr C, Harrison G, Mansel R and Jiang WG: Biphasic effects of 17-β-oestradiol on expression of occludin and transendothelial resistance and paracellular permiability in human vascular endothelial cells. J Cell Physiol. 196:362–369. 2003.
18.	King J, Ofori-Acquah SF, Stevens T, Al-Mehdi A-B, Fodstad O and Jiang WG: Activated leukocyte adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res. 6:478–487. 2004.
19.	Davies G, Jiang WG and Mason MD: Cell-cell adhesion and signalling intermediates in human prostate cancer. J Urol. 163:985–992. 2000.
20.	Berryman M, Franck Z and Bretscher A: Ezrin is concentrated in the apical microvilli of a wide variety of epithelial cells whereas moesin is found primarily in endothelial cells. J Cell Sci. 105:1025–1043. 1993.
21.	Tsukita S and Hieda Y: A new 82-kD barbed end-capping protein (radixin) localized in the cell-to-cell adherens junction: purification and characterization. J Cell Biol. 108:2369–2382. 1989.
22.	Yonemura S and Tsukita S: Direct involvement of ezrin/radixin/moesin (ERM)-binding membrane proteins in the organization of microvilli in collaboration with activated ERM proteins. J Cell Biol. 145:1497–1509. 1999.
23.	Takeuchi K, Sato N, Kasahara H, Funayama N, Nagafuchi A, Yonemura S and Tsukita S: Perturbation of cell adhesion and microvilli formation by antisense oligonucleotides to ERM family members. J Cell Biol. 125:1371–1384. 1994.
24.	Yu Y, Davicioni E, Triche TJ and Merlino G: The homeo-protein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res. 66:1982–1989. 2006.
25.	Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM and Helman LJ: The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 10:182–186. 2004.